When the SGLT2 inhibitor, EMPA, is given in the early stages of T1D, it may promote the ability to thrive by reducing the weight loss associated with T1D, significantly decreased diabetes-associated polydipsia (excessive thirst), significantly lowered fasting blood sugar levels, decreased kidney weights and most importantly, in the current context, reduced retinal abnormalities associated with early DR. The gene discussed is SLC5A2; the disease is diabetes mellitus.